David B Page

Deborah Kuk

Jarushka Naidoo

Jedd D Wolchok

Jianda Yuan

Katherine Panageas

Kita Bogatch

Michael Postow

Parisa Momtaz

Journal for ImmunoTherapy of Cancer

Springer - Publisher Connector

POSTER PRESENTATION Open Access
Patterns of long-term survival following
Ipilimumab (Ipi): the Memorial Sloan Kettering
Cancer Center 10-year metastatic melanoma
(MM) experience
David B Page1*, Jarushka Naidoo1, Parisa Momtaz1, Kita Bogatch1, Deborah Kuk1, Katherine Panageas1,
Jianda Yuan2, Jedd D Wolchok1, Michael Postow1
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Background
In two Phase III randomized trials in MM, Ipi improved
median overall survival (OS) [1,2]. Here, we evaluate OS
and characterize post-Ipi treatment patterns among
long-term survivors from a single-institution cohort of
patients (pts) treated with Ipi.
Methods
Through a search of institutional databases, we identified
766 pts with MM treated with Ipi between 1/1/2003 and
12/31/2013. As of 4/1/2014, 96 pts have survived ≥2 yrs,
measured from first dose of Ipi. OS was calculated utiliz-
ing the Kaplan-Meier method. Disease control was defined
as the duration from initiation of Tx until initiation of
subsequent systemic Tx or death.
Results
With a median follow-up of 17mo (range 0-9yr), the med-
ian OS for the entire cohort of 766 pts was 15mo, with a
2-yr OS of 41%. Of the 80 pts with OS ≥2 yrs post-Ipi for
whom data are available, 75% (n = 60/80) remain alive and
30% (n = 24/80) remain progression-free following Ipi,
with median Ipi disease control of 15mo (range: 3 to 107
+mo). Among pts with progression (n = 56), 57% exhibited
disseminated progression, 29% oligometastatic progres-
sion, and 15% CNS-only progression. The most frequent
Tx at first progression was locoregional (n = 29),
employed at a median of 11mo post-Ipi (range: 3 to 55mo)
and associated with median 15+mos disease control
(range 1 to 73+mo) (table 1). In pts requiring post-Ipi
systemic Tx, long-term disease control was observed
across multiple systemic Tx’s (table 2).
Conclusion
Within this single-institution cohort, the median OS and
2-yr OS were greater than reported previously in Phase III
trials [1,2]. Potential reasons for this survival advantage
1Memorial Sloan Kettering Cancer Center, New York, NY, USA
Full list of author information is available at the end of the article
Table 1 Pts receiving locoregional Tx at first progression.
Locoregional Tx # pts # pts achieving ≥1yr
disease control
CNS, surgery and/or RT 9/80 (11%) 5/9 (56%)
Non-CNS, surgery 11/80 (14%) 8/11 (73%)
Non-CNS, RT 6/80 (8%) 3/6 (50%)
Ablation 2/80 (3%) 1/2 (50%)
Table 2 Post-Ipi Systemic Txs.
Post-Ipi
Systemic Tx
# pts # pts achieving ≥1yr disease
control*
Cytotoxic
Therapy
11/80
(14%)
5/10 (50%)
Anti-PD-1/PD-L1 16/80
(20%)
11/15 (73%)
BRAF inhibitor 10/80
(13%)
7/9 (78%)
Ipi re-induction 18/80
(23%)
5/16 (31%)
Other clinical
trial
13/80
(16%)
1/13 (8%)
*pts with ongoing disease control and <1yr follow up excluded
Page et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P117
http://www.immunotherapyofcancer.org/content/2/S3/P117
© 2014 Page et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
include: referral bias, heterogeneous Ipi dosing/schedule,
and access to subsequent trials (i.e. anti-PD-1/PD-L1,
BRAF inhibitor). The majority of long-term survivors
required subsequent Tx, however prolonged disease
control was achieved with a range of Tx’s. Pts who experi-
ence oligometastatic/CNS-only progression following Ipi
may achieve prolonged disease control with locoregional
Tx alone.
Authors’ details
1Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2Immune
Monitoring Facility, Sloan Kettering Institute, New York, NY, USA.
Published: 6 November 2014
References
1. Hodi F, O’Day S, McDermott D, et al: Improved Survival with Ipilimumab
in patients with metastatic melanoma. N Engl J Med 363:711-23.
2. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for
previously untreated metastatic melanoma. N Engl J Med 364:2517-26.
doi:10.1186/2051-1426-2-S3-P117
Cite this article as: Page et al.: Patterns of long-term survival following
Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year
metastatic melanoma (MM) experience. Journal for ImmunoTherapy of
Cancer 2014 2(Suppl 3):P117.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Page et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P117
http://www.immunotherapyofcancer.org/content/2/S3/P117
Page 2 of 2


Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

file:///data/core-remote/dit/data/Springer-OA/pdf/543/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvMjA1MS0xNDI2LTItUzMtUDExNy5wZGY=.pdf

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

Springer - Publisher Connector